SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare informs about updates

31 Oct 2024 Evaluate
Shilpa Medicare has informed that Shilpa Medicare, Unit VI, Dabaspet, Bengaluru, India was inspected by USFDA on 24, 25 and 28, 29, 30 October 2024. The inspection was the onsite GMP inspection of this Site. The inspection concluded with the issuance of Form 483 with four observations. All observations are procedural in nature. The Company shall respond to the observations within the time frame. This Unit of Shilpa Medicare Ltd. is engaged in the manufacturing, testing and release of Oral Mouth Dissolving Films and Transdermal Systems. The Site has already been approved by MHRA-UK and TGA Australia and has USFDA approval for supplying nutraceutical Oral Film products into US and other markets.

The above information is a part of company’s filings submitted to BSE.


Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×